Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis
Barbara White, Daniel E. Furst, Tracy Frech, Masataka Kuwana, Laura K. Hummers, Wendy Stevens, Suzanne Kafaja, Eun Bong Lee, Oliver Distler, Dinesh Khanna, Christopher P. Denton, Robert Spiera, for the RESOLVE‐1 investigators
IF 2.8ACR Open Rheumatology
초록
Taken together, our findings robustly support routine use of MMF in dcSSc and show benefit especially in early-stage disease. Those patients with high-risk antibodies for lung fibrosis might be especially suitable for MMF treatment.